| Name | 6-N-[(4-nitrophenyl)methyl]-2-N-[[3-(trifluoromethyl)phenyl]methyl]-7H-purine-2,6-diamine |
|---|---|
| Synonyms |
N6-[(4-nitrophenyl)methyl]-N2-[[3-(trifluoromethyl)phenyl]methyl]-1H-Purine-2,6-diamine
N2-(m-Trifluorobenzyl) (N6-(p-nitrobenzyl)purine Purine,5 IP3K Inhibitor N2-(m-Trifluorobenzyl),N6-(p-nitrobenzyl)purine Inositol-1,4,5-trisphosphate 3-Kinase Inhibitor |
| Description | IP3K Inhibitor is a IP3K inhibitor with an IC50 of 10.2 μM. |
|---|---|
| Related Catalog | |
| Target |
IC50: 10.2 μM (IP3K)[1] |
| In Vitro | IP3K Inhibitor binds to the ATP binding site of IP3K with an inhibition constant Ki of 4.3 μM. IP3K Inhibitor is a significantly weaker inhibitor of CDK1 (IC50>100 μM). Upon treatment with IP3K Inhibitor, the intracellular calcium level increases over 1±2 mins in a dose-dependent manner and any subsequent ATP-induced calcium release was almost completely absent at a 20 μM concentration of IP3K Inhibitor[1]. |
| References |
| Molecular Formula | C20H16F3N7O2 |
|---|---|
| Molecular Weight | 443.38200 |
| Exact Mass | 443.13200 |
| PSA | 127.57000 |
| LogP | 4.52220 |
| Symbol |
GHS06 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H300-H319 |
| Precautionary Statements | P264-P301 + P310-P305 + P351 + P338 |
| RIDADR | UN 2811 6.1 / PGIII |